PepGen is temporarily pausing their Phase 2 CONNECT2-EDO51 study in the UK

PepGen, which received early funding from CureDuchenne, announced that they are temporarily pausing their CONNECT2 study in the UK in order to focus resources and first review data from the Phase2 CONNECT1 study being conducted in Canada.   Both CONNECT1 and CONNECT2 studies are for individuals amenable to skipping Exon 51, and data from the CONNECT1 10 mg/kg cohort are expected during the third quarter of 2025. 

Link to press release:  https://www.businesswire.com/news/home/20250304975981/en/PepGen-Announces-Update-to-Phase-2-CONNECT2-EDO51-Study-in-Patients-with-DMD/